Related Experiment Videos
Definitive prenatal diagnosis for type III glycogen storage disease
B Z Yang1, J H Ding, B I Brown
1Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.
American Journal of Human Genetics
|October 1, 1990
Summary
Prenatal diagnosis for type III glycogen storage disease is now possible using immunoblot analysis or a qualitative debranching-enzyme assay. These methods accurately predict affected fetuses, enabling early intervention for this rare genetic disorder.
Area of Science:
- Medical Genetics
- Biochemistry
- Prenatal Diagnostics
Background:
- Glycogen storage disease type III (GSD III) is a rare inherited metabolic disorder.
- It results from a deficiency in the debranching enzyme, leading to glycogen accumulation.
- Accurate prenatal diagnosis is crucial for management and genetic counseling.
Purpose of the Study:
- To evaluate the efficacy of two methods for prenatal diagnosis of GSD III.
- To determine if immunoblot analysis and a qualitative enzyme assay can reliably detect GSD III in fetal cells.
Main Methods:
- Prenatal diagnosis utilized immunoblot analysis with an antibody against debranching enzyme.
- A qualitative assay assessed debranching-enzyme activity by observing polysaccharide persistence in glucose-free medium.
- Cultured amniotic fluid cells from affected and unaffected pregnancies were analyzed.
Main Results:
- Immunoblot analysis correctly predicted two unaffected and one affected fetus from three families.
- The qualitative assay predicted six unaffected and three affected fetuses from nine pregnancies.
- All postnatal confirmations aligned with prenatal predictions, except for one case of spontaneous abortion.
Conclusions:
- Prenatal diagnosis of GSD III is achievable using immunoblot analysis or a qualitative debranching-enzyme assay.
- These methods provide reliable diagnostic capabilities for GSD III during pregnancy.
- Definitive prenatal diagnosis facilitates timely management and informed family planning for GSD III.